UY33552A - Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico. - Google Patents

Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico.

Info

Publication number
UY33552A
UY33552A UY0001033552A UY33552A UY33552A UY 33552 A UY33552 A UY 33552A UY 0001033552 A UY0001033552 A UY 0001033552A UY 33552 A UY33552 A UY 33552A UY 33552 A UY33552 A UY 33552A
Authority
UY
Uruguay
Prior art keywords
acid derivatives
enantiomeric forms
diaminopropionic
procedure
preparing enantiomeric
Prior art date
Application number
UY0001033552A
Other languages
English (en)
Inventor
Joerg Dr Rieke-Zapp
Claus Dieter Dr Graf
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33552(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of UY33552A publication Critical patent/UY33552A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico La in vención se refiere a un procedimiento para preparar las formas enantioméricas de derivados de ácido 2,3-diaminopropiónico de fórmula I,en donde R1, R2 y R3 están definidos como en las reivindicaciones, por resolución de racemato. La separación del racemato en sus enantiómeros tiene lugar a través de la formación de sales diastereómeras al añadir un auxiliar enantioméricamente puro, y la separación subsiguiente mediante cristalización fraccionada.
UY0001033552A 2010-08-12 2011-08-10 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico. UY33552A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12

Publications (1)

Publication Number Publication Date
UY33552A true UY33552A (es) 2012-03-30

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033552A UY33552A (es) 2010-08-12 2011-08-10 Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico.

Country Status (23)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067918B2 (en) 2011-12-06 2015-06-30 Sanofi Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1H-indole-5-carboxylic acid [ (S)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl ]-amide

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
DOP2013000035A (es) 2013-03-15
AU2011288533A1 (en) 2013-02-28
KR20130099044A (ko) 2013-09-05
US8877926B2 (en) 2014-11-04
GT201300038A (es) 2015-06-24
CO6690757A2 (es) 2013-06-17
AR082621A1 (es) 2012-12-19
BR112013002985A2 (pt) 2017-11-07
CA2807979A1 (en) 2012-02-16
WO2012019967A1 (en) 2012-02-16
EP2603491A1 (en) 2013-06-19
CL2013000420A1 (es) 2013-04-05
TW201221504A (en) 2012-06-01
EP2603491B1 (en) 2014-09-24
CR20130059A (es) 2013-03-25
CN103209961A (zh) 2013-07-17
RU2013110525A (ru) 2014-09-20
PE20131326A1 (es) 2013-11-12
JP6000248B2 (ja) 2016-09-28
MA34464B1 (fr) 2013-08-01
MX2013001647A (es) 2013-03-21
US20130211085A1 (en) 2013-08-15
US9434696B2 (en) 2016-09-06
SG187791A1 (en) 2013-03-28
JP2013533296A (ja) 2013-08-22
ECSP13012434A (es) 2013-03-28
US20150018554A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
MX2016012419A (es) Formas solidas de ibrutinib y procesos para la produccion de las mismas.
CO6761376A2 (es) Método de producción de derivado de dihidrobenzofurano ópticamente activo
CO2017001884A2 (es) Polimorfos de selinexor
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
MX2018010199A (es) Proceso para la separacion de enantiomeros de derivados de piperazina.
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
BR112014024493A2 (pt) método para a produção enzimática de isoprenol usando mevalonato como substrato
AR101434A1 (es) Método para producir (r)-1,1,3-trimetil-4-aminoindano
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112018016789A2 (pt) processo para preparação biocatalítica e preparação de um composto
EA201691006A1 (ru) Морфологические формы гексадецилоксипропиловых сложных эфиров фосфоновой кислоты и способы их синтеза
BR112017001177A2 (pt) processo para a purificação de poliovírus a partir de culturas celulares
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
BR112019025028A2 (pt) Método para preparar um composto.
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
EA201391721A1 (ru) Способ получения полиморфной формы i эторикоксиба
BR112013019525A2 (pt) método para a produção de 2,3-butanodiol por fermentação
BR112014019289A8 (pt) Métodos para a preparação do composto de prome-dicamento de piperazina inibidor da ligação do hiv
WO2014127418A8 (en) Conjugate compound and uses of same
EA201590116A1 (ru) Способ получения замещенных триазолопиридинов
BR112013031334A2 (pt) método para preparar zeólitos do tipo lta utilizando um agente de dirigir estrutura novo
BR112015023343A2 (pt) método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir
UY33552A (es) Procedimiento para preparar formas enantiomericas de derivados de acido 2,3-diaminopropionico.
EA201791329A1 (ru) Новые кристаллические формы мононатриевой соли форамсульфурона
NI201300022A (es) Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3 - diaminopropiónico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200821